BETTER CELL LINE FOR MAKING HYBRIDOMAS SECRETING SPECIFIC ANTIBODIES
BETTER CELL LINE FOR MAKING HYBRIDOMAS SECRETING SPECIFIC ANTIBODIES
复制标题
DOI：
10.1038/276269a0
复制
发表时间：
1978-01-01
期刊：
影响因子：
64.8
通讯作者：
KOHLER, G
中科院分区：
文献类型：
--
作者：
SHULMAN, M;WILDE, CD;KOHLER, G
将组织培养的骨髓瘤细胞与免疫小鼠的脾细胞融合，提供了一种获得能产生所需特异性抗体的细胞系（杂交瘤）的通用方法1 - 3。来源于这些骨髓瘤的杂种产生骨髓瘤亲本的免疫球蛋白（Ig）重链和轻链，以及脾细胞亲本的抗原特异性重链和轻链。在两条重链和两条轻链随机结合的条件下，杂交瘤将产生10个不同的Ig分子，而特异性抗体将仅包含总ig4,5的1/16。为了获得只产生特异性抗体的杂交瘤，需要一个肿瘤细胞融合伙伴，该肿瘤细胞本身不产生Ig，但可以与脾脏细胞融合以获得只分泌特异性抗体的杂交瘤。我们在这里报道了这样一个细胞系Sp2/0-Ag14的鉴定。
FUSION of myeloma cells which grow in tissue culture with spleen cells from an immunised mouse provides a general method for obtaining cell lines (hybridomas) which make antibody of the desired specificity1–3. Hybrids derived from these myelomas make the immunoglobulin (Ig) heavy and light chains of the myeloma parent as well as the antigen-specific heavy and light chains of the spleen cell parent. In conditions in which the two heavy and two light chains associate randomly, a hybridoma would make 10 distinct Ig molecules, and the specific antibody would comprise only 1/16 of the total Ig4,5. To obtain hybridomas making only the specific antibodies requires a tumour cell fusion partner that itself makes no Ig but which can nevertheless be fused with spleen cells to obtain hybrids secreting only the specific antibody. We report here the identification of such a cell line, Sp2/0-Ag14.